A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)

Published:2016-02-19 Issue:5 Volume:18 Page:475-482
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Dungan K. M.¹,Weitgasser R.²³,Perez Manghi F.⁴,Pintilei E.⁵,Fahrbach J. L.⁶,Jiang H. H.⁶,Shell J.⁶,Robertson K. E.⁶

Affiliation:

1. Division of Endocrinology, Diabetes and Metabolism; Ohio State University; Columbus OH USA

2. Department of Internal Medicine; Wehrle-Diakonissen Hospital; Salzburg Austria

3. 1st Department of Medicine; Salzburg University Hospital, Paracelsus Medical University; Salzburg Austria

4. Centro de Investigaciones Metabólicas (CINME); Buenos Aires Argentina

5. Department of Medicine; SC Consultmed SRL; Iasi Romania

6. Lilly Research Laboratories; Eli Lilly and Company; Indianapolis IN USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12634/fullpdf

Reference30 articles.

1. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study;Stratton;BMJ,2000

2. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

3. Advantages of extended-release metformin in patients with type 2 diabetes mellitus;Jabbour;Postgrad Med,2011

4. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome;Pongwecharak;Pharm World Sci,2009

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials;Biomedicines;2024-08-23

2. Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus;Pharmacia;2024-08-02

3. Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression;Diabetes, Obesity and Metabolism;2024-03-20

4. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression;2024-01-30

5. Glucagon-like Peptide-1 Agonists;JBJS Reviews;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3